Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Decrease in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 38,895 shares, a decline of 47.6% from the September 15th total of 74,269 shares. Based on an average daily volume of 64,451 shares, the short-interest ratio is presently 0.6 days. Approximately 0.1% of the company’s shares are sold short.

Dogwood Therapeutics Stock Down 1.2%

Dogwood Therapeutics stock traded down $0.01 during midday trading on Thursday, hitting $1.25. 99,769 shares of the stock were exchanged, compared to its average volume of 76,535. Dogwood Therapeutics has a 52-week low of $1.18 and a 52-week high of $7.04. The business’s 50-day moving average price is $1.88 and its 200-day moving average price is $1.72. The stock has a market capitalization of $42.66 million, a price-to-earnings ratio of -0.14 and a beta of 1.92.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.20). On average, sell-side analysts predict that Dogwood Therapeutics will post -0.80 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. HC Wainwright restated a “buy” rating on shares of Dogwood Therapeutics in a report on Wednesday, September 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with herpesvirus reactivation. The company’s research is aimed at addressing chronic conditions for which viral activity may contribute to symptoms and disease progression.

Dogwood’s lead investigational product is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory drug. The therapy has been studied as a potential treatment for fibromyalgia, and the company has also evaluated its broader application in conditions such as long COVID.

The company was formerly known as Virios Therapeutics and adopted the Dogwood Therapeutics name as it expanded its focus on antiviral drug development.